AU2001280368A1 - Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy - Google Patents

Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy

Info

Publication number
AU2001280368A1
AU2001280368A1 AU2001280368A AU8036801A AU2001280368A1 AU 2001280368 A1 AU2001280368 A1 AU 2001280368A1 AU 2001280368 A AU2001280368 A AU 2001280368A AU 8036801 A AU8036801 A AU 8036801A AU 2001280368 A1 AU2001280368 A1 AU 2001280368A1
Authority
AU
Australia
Prior art keywords
antibodies
immunotherapy
stimulating
cells
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280368A
Inventor
Gediminas Greicius
Bernhard B. Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karolinska Innovations AB
Original Assignee
Karolinska Innovations AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations AB filed Critical Karolinska Innovations AB
Publication of AU2001280368A1 publication Critical patent/AU2001280368A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001280368A 2000-08-07 2001-08-07 Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy Abandoned AU2001280368A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0002835A SE0002835D0 (en) 2000-08-07 2000-08-07 Method and kit for production of monoclonal antibodies
SE0002835 2000-08-07
PCT/SE2001/001714 WO2002012535A1 (en) 2000-08-07 2001-08-07 Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy

Publications (1)

Publication Number Publication Date
AU2001280368A1 true AU2001280368A1 (en) 2002-02-18

Family

ID=20280635

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280368A Abandoned AU2001280368A1 (en) 2000-08-07 2001-08-07 Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy

Country Status (4)

Country Link
US (1) US20040005321A1 (en)
AU (1) AU2001280368A1 (en)
SE (1) SE0002835D0 (en)
WO (1) WO2002012535A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004053139A1 (en) * 2002-12-10 2004-06-24 Apollo Life Sciences Limited A method of antibody production
US8815248B2 (en) 2005-06-09 2014-08-26 Gal Markel Modulation of immunity and CEACAM1 activity
CA2760385C (en) * 2009-04-30 2021-04-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anti ceacam1 antibodies and methods of using same
DE102010024636B4 (en) 2010-06-22 2024-04-18 Universität Duisburg-Essen Antibodies, especially for diagnostics
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
JP2015525781A (en) * 2012-07-31 2015-09-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Modulating the immune response
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
MD20160130A2 (en) 2014-04-27 2017-04-30 Ccam Biotherapeutics Ltd. Humanized antibodies against CEACAM1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA919299B (en) * 1990-11-26 1992-08-26 Akzo Nv Method for the production of antibodies
DE69925909T2 (en) * 1998-04-15 2006-05-11 Brigham & Women's Hospital, Inc., Boston T-cell inhibiting receptor compositions and their use
CA2383562A1 (en) * 1999-08-26 2001-03-01 Keith M. Skubitz Peptides capable of modulating the function of cd66 (ceacam) family members

Also Published As

Publication number Publication date
WO2002012535A1 (en) 2002-02-14
SE0002835D0 (en) 2000-08-07
US20040005321A1 (en) 2004-01-08
WO2002012535B1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
EP2940044B8 (en) Anti-tnf alpha antibodies for use in therapy
EP1392361A4 (en) Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
IL205511A0 (en) Methods and compositions for the production of monoclonal antibodies
AU2003257850A1 (en) ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN
AU2003264009A1 (en) Humanized rabbit antibodies
IL156618A0 (en) Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU4935000A (en) Antibodies
AU2003209059A1 (en) Human monoclonal antibodies against membrane proteins
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU5441000A (en) Human monoclonal antibody
HK1048650A1 (en) Methods for enhancing the production of cytokines in cell cultur e
HK1055750A1 (en) Monoclonal antibodies to the human ldl receptor, their production and use
AU2001280368A1 (en) Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy
AU2002251821A1 (en) Nicotine immunogens and antibodies and uses thereof
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same
AU2003210054A1 (en) Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
AU2002953238A0 (en) In vitro immunization
EP1621555A4 (en) Immunogen, composition for immunological use, and method of producing antibody using the same
AU2452301A (en) Protein methylarginine-specific antibodies
EP1380646A4 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
AU2003282241A1 (en) Antibodies for in vitro use
AU2002249221A1 (en) Use of casb7439 (ash2) in the immunotherapy of breast cancer
AU2002321440A1 (en) Expression of modified antibodies in avian cells